Posted by Michael Wonder on 19 Feb 2018
Medication for rare soft-bone disease to be covered by public drug plans in Canada
15 February 2018 - One of the most expensive medications in the world is about to be covered by public drug plans in Canada.
The alliance that negotiates group drug discounts on behalf of Ottawa and the provinces has reached a pricing deal with the maker of Strensiq, an injectable treatment for a rare and potentially fatal soft-bone disease that affects fewer than 100 Canadians.
Strensiq, which can cost more than $1-million per patient per year, is the most expensive prescription medication ever evaluated by Canada's Common Drug Review, the body that advises taxpayer-funded drug plans on whether they should pay for new drugs.
